As of 27 November 2025
Individual Neutral Athletes (AINs) are athletes with Belarusian or Russian passports who have been confirmed as eligible and invited to compete at the Milano Cortina 2026 Olympic Winter Games. The AIN quotas were determined through the existing qualification competitions and the specific eligibility requirements of the International Federations (IFs).
For the Paris 2024 Olympic Games, strict eligibility conditions were established for AINs by the International Olympic Committee (IOC) in December 2023. These conditions will also apply to the Milano Cortina 2026 Olympic Winter Games. More information can be found here.
The Individual Neutral Athlete Eligibility Review Panel (AINERP) evaluates the eligibility of each athlete with a Russian or Belarusian passport to participate in the Milano Cortina 2026 Olympic Winter Games, and that of their support personnel. The IOC has the authority to invite an AIN, and their support personnel, to participate in the Milano Cortina 2026 Olympic Winter Games.
Participation in the Milano Cortina 2026 Olympic Winter Games is subject to the athletes’ acceptance of the individual invitation and signing of the Conditions of Participation applicable to all participants. The form contains a commitment to respect the Olympic Charter, including “the peace mission of the Olympic Movement”. Please find an excerpt from the form here.
The AINERP has reviewed the athletes in accordance with the IOC decision and the principles established.
Following the decision of the AINERP, the following athletes have been declared eligible and have been invited to participate in the Milano Cortina 2026 Olympic Winter Games.
Figure Skating:
Eligible and invited athletes with a Russian passport
Eligible and invited athletes with a Belarusian passport
This list will be updated in line with the decisions of the AINERP. Last update: 27 November 2025.
Deepak Group undertakes mangrove plantation drive on World Environment DaySustainable restoration along the Paniyadra coast,…
•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…
Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…
June 05, 2026 19:30 ET | Source: Oban BioPharma, Inc. STAMFORD, Conn., June 05, 2026…
Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…
June 05, 2026 20:13 ET | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…